Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BYSINYSE:CLDINASDAQ:DTILNASDAQ:KRON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$2.35-4.1%$2.03$0.98▼$3.44$98.77M0.0732,420 shs22,243 shsCLDICalidi Biotherapeutics$0.23+2.8%$0.38$0.20▼$3.89$7.31M1.071.00 million shs469,966 shsDTILPrecision BioSciences$4.20-2.3%$4.99$3.61▼$11.09$47.68M1.48223,267 shs158,073 shsKRONKronos Bio$0.88+1.5%$0.79$0.65▼$1.60$53.72M1.64360,698 shs54,089 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring-4.08%-14.23%+35.45%+50.16%-2.08%CLDICalidi Biotherapeutics+2.82%-19.30%-34.34%-58.71%+22,999,900.00%DTILPrecision BioSciences-2.33%-7.28%-13.58%-6.46%-56.83%KRONKronos Bio0.00%0.00%+31.70%+8.91%-29.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/ACLDICalidi Biotherapeutics0.2101 of 5 stars0.03.00.00.00.60.00.6DTILPrecision BioSciences4.5561 of 5 stars3.53.00.04.62.91.71.3KRONKronos Bio3.6497 of 5 stars3.23.00.00.03.34.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpring 0.00N/AN/AN/ACLDICalidi Biotherapeutics 0.00N/AN/AN/ADTILPrecision BioSciences 3.00Buy$47.001,019.05% UpsideKRONKronos Bio 2.33Hold$1.6384.66% UpsideCurrent Analyst Ratings BreakdownLatest CLDI, BYSI, KRON, and DTIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpringN/AN/AN/AN/A($0.37) per shareN/ACLDICalidi Biotherapeutics$50K146.25N/AN/A($2.32) per share-0.10DTILPrecision BioSciences$68.70M0.68N/AN/A$6.87 per share0.61KRONKronos Bio$9.85M5.45N/AN/A$1.45 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/ACLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/ADTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)KRONKronos Bio-$86.08M-$1.07N/AN/AN/A-701.53%-64.22%-47.17%8/6/2025 (Estimated)Latest CLDI, BYSI, KRON, and DTIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AKRONKronos BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/A2.492.49CLDICalidi BiotherapeuticsN/A0.190.19DTILPrecision BioSciences0.456.626.62KRONKronos BioN/A12.9312.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%CLDICalidi Biotherapeutics12.53%DTILPrecision BioSciences37.99%KRONKronos Bio64.09%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%CLDICalidi Biotherapeutics6.70%DTILPrecision BioSciences4.00%KRONKronos Bio24.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableCLDICalidi Biotherapeutics3831.79 million20.04 millionN/ADTILPrecision BioSciences20011.09 million10.64 millionNo DataKRONKronos Bio10061.05 million46.16 millionOptionableCLDI, BYSI, KRON, and DTIL HeadlinesRecent News About These CompaniesKronos Bio (NASDAQ:KRON) Rating Increased to Hold at Wall Street ZenJune 21, 2025 | marketbeat.comKronos Bio Completes Merger with Concentra BiosciencesJune 20, 2025 | tipranks.comKronos Bio, Inc. (NASDAQ:KRON) Short Interest UpdateJune 17, 2025 | marketbeat.comInsider Selling: Kronos Bio, Inc. (NASDAQ:KRON) CEO Sells 24,838 Shares of StockJune 7, 2025 | insidertrades.comKronos Bio, Inc. (NASDAQ:KRON) CEO Deborah Knobelman Sells 24,838 SharesJune 6, 2025 | marketbeat.comKronos Bio sends Cambridge lab space back to marketJune 5, 2025 | bizjournals.comKronos Bio Terminates Cambridge Lease AgreementJune 5, 2025 | tipranks.comOrca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial OfficerJune 4, 2025 | finance.yahoo.comKronos Bio, Board Sued by Shareholder Over Concentra Buyout DealMay 21, 2025 | news.bloomberglaw.comNConcentra Biosciences Agrees to Acquire Kronos BioMay 5, 2025 | contractpharma.comCKRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRONMay 4, 2025 | businesswire.comConcentra To Acquire Kronos BioMay 3, 2025 | nasdaq.comConcentra acquires struggling small-molecule biotech KronosMay 2, 2025 | fiercebiotech.comFKronos shares slump on Concentra takeover newsMay 2, 2025 | thepharmaletter.comTSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRONMay 1, 2025 | prnewswire.comAfter hunt for alternatives, Kronos Bio selects Tang Capital's Concentra for a dealMay 1, 2025 | endpts.comEKronos Bio Agrees to Be Acquired by Concentra BiosciencesMay 1, 2025 | marketwatch.comShareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public ShareholdersMay 1, 2025 | businesswire.comKRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to ShareholdersMay 1, 2025 | businesswire.comKronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value RightMay 1, 2025 | finance.yahoo.comKronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value RightMay 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLDI, BYSI, KRON, and DTIL Company DescriptionsBeyondSpring NASDAQ:BYSI$2.35 -0.10 (-4.08%) As of 06/30/2025 04:00 PM EasternBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Calidi Biotherapeutics NYSE:CLDI$0.23 +0.01 (+2.82%) As of 06/30/2025 04:00 PM EasternCalidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Precision BioSciences NASDAQ:DTIL$4.20 -0.10 (-2.33%) As of 06/30/2025 04:00 PM EasternPrecision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Kronos Bio NASDAQ:KRON$0.88 +0.01 (+1.49%) As of 06/20/2025 This is a fair market value price provided by Polygon.io. Learn more.Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
